AI Summary
We reviewed 31 live results for tnf blocker and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Tnf Blocker and Biosimilar.
Comparison Table
Recommended
Hyrimoz (adalimumab-adaz)
Source: Sandoz Inc.
Description
Hyrimoz (adalimumab-adaz) is a prescription biologic medication and an FDA-approved biosimilar to Humira. As a Tumor Necrosis Factor (TNF) blocker, it is used to treat chronic inflammatory diseases including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis. It is available as a subcutaneous injection via the Sensoready Pen autoinjector or a prefilled syringe.
Best for
Rheumatoid arthritis patients, Crohn's disease management, Plaque psoriasis treatment and Biosimilar therapy seekers
View Details
Rating
Yuflyma (adalimumab-aaty)
Source: Celltrion USA, Inc.
Description
Yuflyma is a high-concentration (100 mg/mL), citrate-free, and latex-free biosimilar to Humira (adalimumab), classified as a TNF blocker. It is indicated for the treatment of various inflammatory conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Available in single-dose autoinjectors and prefilled syringes at strengths like 40 mg/0.4 mL and 80 mg/0.8 mL, this biologic medication offers room-temperature stability for up to 31 days, providing flexibility for autoimmune patient care.
Best for
rheumatoid arthritis treatment, citrate-free injection preference, Humira biosimilar seekers, Crohn's disease management and flexible storage needs
View Details
Rating
ABRILADA (adalimumab-afzb)
Source: Pfizer Inc.
Description
ABRILADA (adalimumab-afzb) is a biologic medication and tumor necrosis factor (TNF) blocker designed to treat various inflammatory conditions. As an FDA-approved interchangeable biosimilar to Humira®, it can be substituted at the pharmacy level. This citrate-free medication is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is available in several forms including a single-dose prefilled pen (ABRILADA Pen), single-dose prefilled syringe, and institutional use vial in various strengths.
Best for
rheumatoid arthritis patients, humira biosimilar alternatives, adults with plaque psoriasis, citrate-free injection preference and crohn's disease management
View Details
Rating
| Compare | Hyrimoz (adalimumab-adaz) | Yuflyma (adalimumab-aaty) | ABRILADA (adalimumab-afzb) |
|---|---|---|---|
| Source | Sandoz Inc. | Celltrion USA, Inc. | Pfizer Inc. |
| Description | Hyrimoz (adalimumab-adaz) is a prescription biologic medication and an FDA-approved biosimilar to Humira. As a Tumor Necrosis Factor (TNF) blocker, it is used to treat chronic inflammatory diseases including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), Crohn’s disease (CD), ulcerative colitis (UC), and plaque psoriasis. It is available as a subcutaneous injection via the Sensoready Pen autoinjector or a prefilled syringe. | Yuflyma is a high-concentration (100 mg/mL), citrate-free, and latex-free biosimilar to Humira (adalimumab), classified as a TNF blocker. It is indicated for the treatment of various inflammatory conditions including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. Available in single-dose autoinjectors and prefilled syringes at strengths like 40 mg/0.4 mL and 80 mg/0.8 mL, this biologic medication offers room-temperature stability for up to 31 days, providing flexibility for autoimmune patient care. | ABRILADA (adalimumab-afzb) is a biologic medication and tumor necrosis factor (TNF) blocker designed to treat various inflammatory conditions. As an FDA-approved interchangeable biosimilar to Humira®, it can be substituted at the pharmacy level. This citrate-free medication is indicated for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. It is available in several forms including a single-dose prefilled pen (ABRILADA Pen), single-dose prefilled syringe, and institutional use vial in various strengths. |
| Best for | Rheumatoid arthritis patients, Crohn's disease management, Plaque psoriasis treatment and Biosimilar therapy seekers | rheumatoid arthritis treatment, citrate-free injection preference, Humira biosimilar seekers, Crohn's disease management and flexible storage needs | rheumatoid arthritis patients, humira biosimilar alternatives, adults with plaque psoriasis, citrate-free injection preference and crohn's disease management |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Hyrimoz (adalimumab-adaz) from Sandoz Inc.."
I picked this because Hyrimoz is a clinically validated, FDA-approved biosimilar that offers a reliable and potentially more cost-effective alternative to Humira for managing multiple autoimmune conditions.
Share this search
Related Finds